Enveric Biosciences (NASDAQ:ENVB) Stock Price Up 1.1% – What’s Next?

Shares of Enveric Biosciences, Inc. (NASDAQ:ENVB) shot up 1.1% during trading on Monday . The stock traded as high as $0.48 and last traded at $0.48. 265,195 shares traded hands during trading, a decline of 86% from the average session volume of 1,847,275 shares. The stock had previously closed at $0.47.

Enveric Biosciences Trading Down 7.8 %

The company’s 50-day moving average is $0.48 and its 200 day moving average is $0.59.

Enveric Biosciences (NASDAQ:ENVB) last released its earnings results on Monday, August 12th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.30. Equities analysts expect that Enveric Biosciences, Inc. will post -2.08 EPS for the current year.

Institutional Investors Weigh In On Enveric Biosciences

An institutional investor recently bought a new position in Enveric Biosciences stock. Virtu Financial LLC bought a new stake in Enveric Biosciences, Inc. (NASDAQ:ENVB) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 33,835 shares of the company’s stock, valued at approximately $34,000. Virtu Financial LLC owned approximately 0.44% of Enveric Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 13.82% of the company’s stock.

Enveric Biosciences Company Profile

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.